Učitavanje...
Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
BACKGROUND: Omalizumab, is a humanized anti-IgE monoclonal antibody used to treat allergic asthma. Decreased serum IgE levels, lower eosinophil and B cell counts have been noted as a result of treatment. In vitro studies and animal models support the hypothesis that omalizumab inhibits IgE synthesis...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3875359/ https://ncbi.nlm.nih.gov/pubmed/24004581 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-7022-3-29 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|